181 related articles for article (PubMed ID: 28667226)
1. A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia.
Fabbri A; Grundy Q; Mintzes B; Swandari S; Moynihan R; Walkom E; Bero LA
BMJ Open; 2017 Jun; 7(6):e016701. PubMed ID: 28667226
[TBL] [Abstract][Full Text] [Related]
2. Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study.
Parker L; Karanges EA; Bero L
BMJ Open; 2019 Feb; 9(2):e024928. PubMed ID: 30782921
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical industry funding of events for healthcare professionals on non-vitamin K oral anticoagulants in Australia: an observational study.
Behdarvand B; Karanges EA; Bero L
BMJ Open; 2019 Aug; 9(8):e030253. PubMed ID: 31434780
[TBL] [Abstract][Full Text] [Related]
4. Pharmaceutical industry funding of educational events for pharmacists in Australia: an analysis of data from the first 6 months of a mandatory disclosure programme.
Robertson J; Walkom E; Moynihan R; Bero L; Henry D
Int J Pharm Pract; 2010 Apr; 18(2):88-92. PubMed ID: 20441117
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan.
Saito H; Ozaki A; Sawano T; Shimada Y; Tanimoto T
JAMA Netw Open; 2019 Apr; 2(4):e192834. PubMed ID: 31026027
[TBL] [Abstract][Full Text] [Related]
6. Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries.
Fabbri A; Santos A; Mezinska S; Mulinari S; Mintzes B
Int J Health Policy Manag; 2018 Jun; 7(6):504-509. PubMed ID: 29935127
[TBL] [Abstract][Full Text] [Related]
7. How do health consumer organisations in Australia manage pharmaceutical industry sponsorship? A cross-sectional study.
Lau E; Fabbri A; Mintzes B
Aust Health Rev; 2019 Aug; 43(4):474-480. PubMed ID: 30021681
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceutical industry payments and assisted reproduction in Australia: a retrospective observational study.
Karanges EA; Nangla C; Parker L; Fabbri A; Farquhar C; Bero L
BMJ Open; 2021 Aug; 11(9):e049710. PubMed ID: 34465582
[TBL] [Abstract][Full Text] [Related]
9. Interactions between physicians and the pharmaceutical industry: what does the literature say?
Lexchin J
CMAJ; 1993 Nov; 149(10):1401-7. PubMed ID: 8221424
[TBL] [Abstract][Full Text] [Related]
10. Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and over-active bladder syndrome? An Australian cohort study.
Mintzes B; Swandari S; Fabbri A; Grundy Q; Moynihan R; Bero L
BMJ Open; 2018 Feb; 8(2):e019027. PubMed ID: 29440213
[TBL] [Abstract][Full Text] [Related]
11. Quantifying Industry Spending on Promotional Events Using Open Payments Data.
Grundy Q; Held F; MacIsaac M; Baugh CM; Campbell EG; Bero L
JAMA Health Forum; 2024 Jun; 5(6):e241581. PubMed ID: 38941087
[TBL] [Abstract][Full Text] [Related]
12. Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry's Disclosure UK database, 2015 and 2016 cohorts.
Mulinari S; Ozieranski P
BMJ Open; 2018 Oct; 8(10):e023094. PubMed ID: 30344175
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical Industry Funding of Health Consumer Groups in Australia: A Cross-sectional Analysis.
Fabbri A; Swandari S; Lau E; Vitry A; Mintzes B
Int J Health Serv; 2019 Apr; 49(2):273-293. PubMed ID: 30646806
[TBL] [Abstract][Full Text] [Related]
14. Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan.
Sawano T; Ozaki A; Saito H; Shimada Y; Tanimoto T
JAMA Netw Open; 2019 May; 2(5):e193817. PubMed ID: 31099864
[TBL] [Abstract][Full Text] [Related]
15. Industry payments to Australian medical oncologists and clinical haematologists: a cross-sectional analysis of publicly available disclosures.
Pokorny AMJ; Bero LA; Moynihan R; Mintzes BJ
Intern Med J; 2021 Nov; 51(11):1816-1824. PubMed ID: 32744396
[TBL] [Abstract][Full Text] [Related]
16. Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe.
Ozieranski P; Martinon L; Jachiet PA; Mulinari S
Int J Health Policy Manag; 2022 Dec; 11(12):2842-2859. PubMed ID: 35297231
[TBL] [Abstract][Full Text] [Related]
17. Cross-sectional analysis of pharmaceutical payments to Japanese board-certified gastroenterologists between 2016 and 2019.
Murayama A; Kamamoto S; Kawashima M; Saito H; Yamashita E; Tanimoto T; Ozaki A
BMJ Open; 2023 Apr; 13(4):e068237. PubMed ID: 37072354
[TBL] [Abstract][Full Text] [Related]
18. Payments reported by the pharmaceutical industry in Ireland from 2015 to 2019: An observational study.
Moriarty F; Larkin J; Fahey T
Health Policy; 2021 Oct; 125(10):1297-1304. PubMed ID: 34429238
[TBL] [Abstract][Full Text] [Related]
19. Pharmaceutical industry payments to leaders of professional medical associations in Australia: Focus on cardiovascular disease and diabetes.
Karanges EA; Ting N; Parker L; Fabbri A; Bero L
Aust J Gen Pract; 2020 Mar; 49(3):151-154. PubMed ID: 32113215
[TBL] [Abstract][Full Text] [Related]
20. "Asset exchange"-interactions between patient groups and pharmaceutical industry: Australian qualitative study.
Parker L; Fabbri A; Grundy Q; Mintzes B; Bero L
BMJ; 2019 Dec; 367():l6694. PubMed ID: 31831471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
